isoflavones / ROS Cancer Research Results

isoFl, isoflavones: Click to Expand ⟱
Features:
Isoflavones occur in many plant species, but are especially high in soybeans.
Major isoflavones in soybean are genistein and daidzein
Supplementation may help lower the risk of hormone-related cancers.

Isoflavones — plant-derived polyphenolic compounds belonging to the flavonoid family and functioning as phytoestrogens with selective estrogen receptor modulator-like activity. The principal dietary soy isoflavones are genistein, daidzein, and glycitein, occurring largely as the glycosides genistin, daidzin, and glycitin before intestinal hydrolysis. Common abbreviations include IFs, soy isoflavones, and SIFs. Soybeans and soy foods are the major human dietary sources, while red clover and other legumes contain additional isoflavones such as biochanin A and formononetin. Genistein is substantially more mechanistically characterized than other members of the class, so many anticancer effects attributed broadly to isoflavones are principally supported by genistein studies. Isoflavones preferentially activate ERβ at physiologically relevant concentrations but can activate ERα as exposure increases, making biological effects strongly dependent on dose, tissue, estrogen-receptor composition, metabolism, and individual equol-producing status.

Primary mechanisms (ranked):

  1. Selective estrogen receptor modulation with preferential ERβ agonism at lower concentrations and increasingly mixed ERβ/ERα activity at higher concentrations.
  2. Suppression of proliferative survival signaling including PI3K/Akt/mTOR, NF-κB, JAK/STAT, MAPK/ERK, and Wnt/β-catenin pathways, particularly for genistein.
  3. Induction of cell-cycle arrest and mitochondrial apoptosis through Bcl-2 family modulation, caspase activation, and loss of mitochondrial membrane potential.
  4. Suppression of epithelial-mesenchymal transition, cancer stem-cell phenotypes, migration, invasion, and metastatic signaling.
  5. Antiangiogenic activity and inhibition of tumor-associated growth signaling.
  6. Epigenetic modulation, including altered DNA methylation and re-expression of tumor-suppressive pathways such as ERβ in some prostate-cancer models.
  7. ROS modulation is secondary and strongly concentration- and model-dependent: antioxidant activity can occur at physiological exposure, whereas high experimental concentrations of genistein can increase mitochondrial ROS and promote apoptosis.

Bioavailability / PK relevance: Orally administered isoflavone glycosides are hydrolyzed in the intestine and absorbed as aglycones, followed by extensive glucuronidation and sulfation. Circulating genistein and daidzein therefore consist predominantly of conjugated metabolites, with only a small fraction present as unconjugated biologically active aglycone. Genistein generally produces greater systemic exposure than daidzein. Daidzein may be converted by intestinal microbiota to equol, but only a subset of individuals consistently produce substantial equol, creating marked interindividual variability. Food matrix, intestinal transit, microbiome composition, glycoside form, and formulation materially affect exposure.

In-vitro vs systemic exposure relevance: A major translational limitation exists. Many direct anticancer experiments use approximately 25–100 µM genistein, with some cytotoxic IC50 values exceeding 100 µM, whereas unconjugated genistein after ordinary dietary or supplemental exposure is generally far below these concentrations and represents only a small fraction of circulating total isoflavones. ERβ-mediated signaling and other high-affinity endocrine effects can occur at substantially lower concentrations and are therefore more pharmacologically plausible in humans than many high-concentration kinase inhibition, ROS, or direct cytotoxicity findings.

Clinical evidence status: Human evidence is substantial for dietary exposure and supplement safety but limited for treatment of established cancer. Small randomized trials in prostate cancer demonstrate changes in tumor-associated molecular biomarkers, but convincing reductions in tumor progression, recurrence, or cancer mortality have not been established in therapeutic RCTs. Observational studies associate soy/isoflavone intake with lower incidence or recurrence of some hormone-related cancers, including breast cancer, but these data do not establish treatment efficacy. Isoflavones are therefore best classified as dietary/chemopreventive candidates with human biomarker and observational evidence rather than established anticancer drugs or standard adjunctive cancer therapy.

Cancer-Relevant Isoflavone Mechanisms

Rank Pathway / Axis Cancer Cells Normal Cells Primary Effect Notes / Interpretation
1 Estrogen receptor signaling ERβ ↑; ERα variable ↑ (dose-dependent) ERβ ↑; ERα variable ↑ Tissue-selective estrogen signaling Genistein and daidzein preferentially activate ERβ at lower concentrations. At higher concentrations ERα activation becomes more important, making tumor ERα/ERβ balance a major determinant of response.
2 PI3K Akt mTOR survival signaling ↓ ↔ or ↓ (context-dependent) Reduced proliferation and survival Best supported for genistein. Often linked to reduced Akt phosphorylation and downstream mitochondrial apoptosis.
3 Mitochondrial apoptosis ↑ ↔ (context-dependent) Programmed cell death Bax/Bcl-2 balance shifts toward apoptosis, mitochondrial membrane potential decreases, and cytochrome-dependent caspase pathways may become activated.
4 Caspase cascade Caspase-3 ↑; Caspase-7 ↑ ↔ Execution of apoptosis Observed in multiple genistein and daidzein cancer models but commonly at concentrations above typical free systemic exposure.
5 Bcl-2 family balance Bcl-2 ↓; Bax ↑ ↔ or mixed Lower apoptotic threshold Contributes to mitochondrial permeabilization and downstream caspase activation.
6 Wnt β-catenin signaling ↓ ↔ or ↓ (context-dependent) Reduced stemness, proliferation, and invasion Particularly relevant to experimental cancer stem-cell and EMT models.
7 Epithelial mesenchymal transition ↓ ↔ Reduced invasion and metastatic phenotype Genistein can suppress EMT-associated transcriptional programs including Snail, Slug, ZEB-related, and β-catenin signaling in model-dependent systems.
8 Cancer stem-cell phenotype ↓ Not established Reduced self-renewal and tumor-initiating characteristics Reported effects include reductions in stemness-associated phenotypes and markers, but evidence is primarily preclinical.
9 NF-κB inflammatory survival signaling ↓ ↓ (context-dependent) Reduced inflammatory and anti-apoptotic signaling One component of the pleiotropic signaling effects particularly associated with genistein.
10 JAK STAT signaling ↓ (model-dependent) ↔ or ↓ Reduced proliferation and survival signaling Evidence varies substantially by tumor model and individual isoflavone.
11 MAPK ERK signaling ↓ or mixed (context-dependent) Mixed Altered proliferation and stress signaling Direction varies with receptor status, dose, cell type, and duration of exposure.
12 Cell-cycle regulation CDK activity ↓; cell-cycle arrest ↑ ↔ or ↓ proliferation Suppression of cellular proliferation Genistein can produce G1/S or G2/M arrest depending on tumor model and concentration.
13 Angiogenesis ↓ ↔ or ↓ (context-dependent) Reduced tumor vascular support Primarily supported by preclinical genistein studies.
14 Epigenetic regulation Aberrant methylation ↓ (model-dependent) Mixed Re-expression of tumor-suppressive programs Physiologically relevant genistein concentrations have reduced ERβ promoter methylation and increased ERβ expression in some prostate-cancer models.
15 Mitochondrial ROS increase ROS ↑ (high concentration only) ROS ↓ or ↔ (context-dependent) Oxidative stress-mediated apoptosis Secondary mechanism. Pro-oxidant effects commonly require tens to hundreds of micromolar genistein, while lower exposures may instead be antioxidant.
16 Chemosensitization ↑ (model-dependent) Not established Potential enhancement of anticancer-drug response Synergy with several chemotherapeutic agents has been reported preclinically, but this is not an established clinical adjunct indication.
17 Clinical Translation Constraint High-concentration mechanisms often not systemically achievable Extensive conjugation limits free aglycone exposure Limits translation of direct cytotoxic mechanisms Free circulating genistein is only a small fraction of total plasma genistein. Many experimental anticancer effects occur at 25–100 µM or higher, substantially exceeding typical unconjugated systemic concentrations. Composition of supplements and equol-producing status add further heterogeneity.


Alzheimer’s disease relevance: Soy isoflavones have plausible neurological mechanisms through ERβ signaling, antioxidant and anti-inflammatory effects, vascular effects, and metabolism of daidzein to equol. However, direct clinical evidence does not support isoflavones as an established Alzheimer treatment. In a randomized trial of patients with Alzheimer’s disease, 100 mg/day soy isoflavones for six months produced no significant overall cognitive benefit versus placebo. Exploratory associations between higher equol exposure and selected cognitive measures suggest that microbiome-dependent metabolism may modify response, but this remains unconfirmed.

Alzheimer-Relevant Isoflavone Effects

Rank Pathway / Axis Modulation Primary Effect Notes / Interpretation
1 Estrogen receptor beta signaling ↑ Neuroendocrine and neuronal signaling Mechanistically plausible because genistein and daidzein preferentially activate ERβ, which is expressed in brain regions involved in cognition.
2 Oxidative stress ↓ (context-dependent) Potential neuronal protection Predominantly preclinical evidence; effects depend on concentration and individual isoflavone.
3 Neuroinflammatory signaling ↓ (context-dependent) Potential reduction in inflammatory injury Primarily mechanistic and preclinical evidence.
4 Equol production ↑ biological activity in equol producers Possible modification of cognitive response Daidzein-to-equol conversion depends on intestinal microbiota and occurs only in a subset of individuals.
5 Clinical cognition ↔ No established cognitive improvement in Alzheimer’s disease A six-month randomized trial using 100 mg/day soy isoflavones found no significant cognitive benefit versus placebo.


ROS, Reactive Oxygen Species: Click to Expand ⟱
Source: HalifaxProj (inhibit)
Type:
Reactive oxygen species (ROS) are highly reactive molecules that contain oxygen and can lead to oxidative stress in cells. They play a dual role in cancer biology, acting as both promoters and suppressors of cancer.
ROS can cause oxidative damage to DNA, leading to mutations that may contribute to cancer initiation and progression. So normally you want to inhibit ROS to prevent cell mutations.
However excessive ROS can induce apoptosis (programmed cell death) in cancer cells, potentially limiting tumor growth. Chemotherapy typically raises ROS.
-mitochondria is the main source of reactive oxygen species (ROS) (and the ETC is heavily related)
ROS Homeostasis in Cancer Cells and Its Potential as a Therapeutic Target

"Reactive oxygen species (ROS) are two electron reduction products of oxygen, including superoxide anion, hydrogen peroxide, hydroxyl radical, lipid peroxides, protein peroxides and peroxides formed in nucleic acids 1. They are maintained in a dynamic balance by a series of reduction-oxidation (redox) reactions in biological systems and act as signaling molecules to drive cellular regulatory pathways."
"During different stages of cancer formation, abnormal ROS levels play paradoxical roles in cell growth and death 8. A physiological concentration of ROS that maintained in equilibrium is necessary for normal cell survival. Ectopic ROS accumulation promotes cell proliferation and consequently induces malignant transformation of normal cells by initiating pathological conversion of physiological signaling networks. Excessive ROS levels lead to cell death by damaging cellular components, including proteins, lipid bilayers, and chromosomes. Therefore, both scavenging abnormally elevated ROS to prevent early neoplasia and facilitating ROS production to specifically kill cancer cells are promising anticancer therapeutic strategies, in spite of their contradictoriness and complexity."
"ROS are the collection of derivatives of molecular oxygen that occur in biology, which can be categorized into two types, free radicals and non-radical species. The non-radical species are hydrogen peroxide (H 2O 2 ), organic hydroperoxides (ROOH), singlet molecular oxygen ( 1 O 2 ), electronically excited carbonyl, ozone (O3 ), hypochlorous acid (HOCl, and hypobromous acid HOBr). Free radical species are super-oxide anion radical (O 2•−), hydroxyl radical (•OH), peroxyl radical (ROO•) and alkoxyl radical (RO•) [130]. Any imbalance of ROS can lead to adverse effects. H2 O 2 and O 2 •− are the main redox signalling agents. The cellular concentration of H2 O 2 is about 10−8 M, which is almost a thousand times more than that of O2 •−".
"Radicals are molecules with an odd number of electrons in the outer shell [393,394]. A pair of radicals can be formed by breaking a chemical bond or electron transfer between two molecules."

Recent investigations have documented that polyphenols with good antioxidant activity may exhibit pro-oxidant activity in the presence of copper ions, which can induce apoptosis in various cancer cell lines but not in normal cells. "We have shown that such cell growth inhibition by polyphenols in cancer cells is reversed by copper-specific sequestering agent neocuproine to a significant extent whereas iron and zinc chelators are relatively ineffective, thus confirming the role of endogenous copper in the cytotoxic action of polyphenols against cancer cells. Therefore, this mechanism of mobilization of endogenous copper." > Ions could be one of the important mechanisms for the cytotoxic action of plant polyphenols against cancer cells and is possibly a common mechanism for all plant polyphenols. In fact, similar results obtained with four different polyphenolic compounds in this study, namely apigenin, luteolin, EGCG, and resveratrol, strengthen this idea.
Interestingly, the normal breast epithelial MCF10A cells have earlier been shown to possess no detectable copper as opposed to breast cancer cells [24], which may explain their resistance to polyphenols apigenin- and luteolin-induced growth inhibition as observed here (Fig. 1). We have earlier proposed [25] that this preferential cytotoxicity of plant polyphenols toward cancer cells is explained by the observation made several years earlier, which showed that copper levels in cancer cells are significantly elevated in various malignancies. Thus, because of higher intracellular copper levels in cancer cells, it may be predicted that the cytotoxic concentrations of polyphenols required would be lower in these cells as compared to normal cells."

Majority of ROS are produced as a by-product of oxidative phosphorylation, high levels of ROS are detected in almost all cancers.
-It is well established that during ER stress, cytosolic calcium released from the ER is taken up by the mitochondrion to stimulate ROS overgeneration and the release of cytochrome c, both of which lead to apoptosis.

Note: Products that may raise ROS can be found using this database, by:
Filtering on the target of ROS, and selecting the Effect Direction of ↑

Targets to raise ROS (to kill cancer cells):
• NADPH oxidases (NOX): NOX enzymes are involved in the production of ROS.
    -Targeting NOX enzymes can increase ROS levels and induce cancer cell death.
    -eNOX2 inhibition leads to a high NADH/NAD⁺ ratio which can lead to increased ROS
• Mitochondrial complex I: Inhibiting can increase ROS production
• P53: Activating p53 can increase ROS levels(by inducing the expression of pro-oxidant genes)
• Nrf2 inhibition: regulates the expression of antioxidant genes. Inhibiting Nrf2 can increase ROS levels
• Glutathione (GSH): an antioxidant. Depleting GSH can increase ROS levels
• Catalase: Catalase converts H2O2 into H2O+O. Inhibiting catalase can increase ROS levels
• SOD1: converts superoxide into hydrogen peroxide. Inhibiting SOD1 can increase ROS levels
• PI3K/AKT pathway: regulates cell survival and metabolism. Inhibiting can increase ROS levels
• HIF-1α inhibition: regulates genes involved in metabolism and angiogenesis. Inhibiting HIF-1α can increase ROS
• Glycolysis: Inhibiting glycolysis can increase ROS levels • Fatty acid oxidation: Cancer cells often rely on fatty acid oxidation for energy production.
-Inhibiting fatty acid oxidation can increase ROS levels
• ER stress: Endoplasmic reticulum (ER) stress can increase ROS levels
• Autophagy: process by which cells recycle damaged organelles and proteins.
-Inhibiting autophagy can increase ROS levels and induce cancer cell death.
• KEAP1/Nrf2 pathway: regulates the expression of antioxidant genes.
    -Inhibiting KEAP1 or activating Nrf2 can increase ROS levels and induce cancer cell death.
• DJ-1: regulates the expression of antioxidant genes. Inhibiting DJ-1 can increase ROS levels
• PARK2: regulates the expression of antioxidant genes. Inhibiting PARK2 can increase ROS levels
• SIRT1 inhibition:regulates the expression of antioxidant genes. Inhibiting SIRT1 can increase ROS levels
• AMPK activation: regulates energy metabolism and can increase ROS levels when activated.
• mTOR inhibition: regulates cell growth and metabolism. Inhibiting mTOR can increase ROS levels
• HSP90 inhibition: regulates protein folding and can increase ROS levels when inhibited.
• Proteasome: degrades damaged proteins. Inhibiting the proteasome can increase ROS levels
• Lipid peroxidation: a process by which lipids are oxidized, leading to the production of ROS.
    -Increasing lipid peroxidation can increase ROS levels
• Ferroptosis: form of cell death that is regulated by iron and lipid peroxidation.
    -Increasing ferroptosis can increase ROS levels
• Mitochondrial permeability transition pore (mPTP): regulates mitochondrial permeability.
    -Opening the mPTP can increase ROS levels
• BCL-2 family proteins: regulate apoptosis and can increase ROS levels when inhibited.
• Caspase-independent cell death: a form of cell death that is regulated by ROS.
    -Increasing caspase-independent cell death can increase ROS levels
• DNA damage response: regulates the repair of DNA damage. Increasing DNA damage can increase ROS
• Epigenetic regulation: process by which gene expression is regulated.
    -Increasing epigenetic regulation can increase ROS levels

-PKM2, but not PKM1, can be inhibited by direct oxidation of cysteine 358 as an adaptive response to increased intracellular reactive oxygen species (ROS)

ProOxidant Strategy:(inhibit the Mevalonate Pathway (likely will also inhibit GPx)
-HydroxyCitrate (HCA) found as supplement online and typically used in a dose of about 1.5g/day or more
-Atorvastatin typically 40-80mg/day, -Dipyridamole typically 200mg 2x/day Combined effect research
-Lycopene typically 100mg/day range (note debatable as it mainly lowers NRF2)

Dual Role of Reactive Oxygen Species and their Application in Cancer Therapy 
ROS-Inducing Interventions in Cancer — Canonical + Mechanistic Reference
-generated from AI and Cancer database
ROS rating:  +++ strong | ++ moderate | + weak | ± mixed | 0 none
NRF2:        ↓ suppressed | ↑ activated | ± mixed | 0 none
Conditions:  [D] dose  [Fe] metal  [M] metabolic  [O₂] oxygen
             [L] light [F] formulation [T] tumor-type [C] combination




Item ROS↑ NRF2 Condition Mechanism Class Remarks 



ROS">Piperlongumine
+++ ↓ [D][T] ROS-dominant






ROS">Shikonin
+++↓/±[D][T]ROS-dominant






ROS">Vitamin K3 (menadione)
+++↓[D]ROS-dominant






ROS">Copper (ionic / nano)
+++↓[Fe][F]ROS-dominant






ROS">Sodium Selenite
+++↓[D]ROS-dominant






ROS">Juglone
+++↓[D]ROS-dominant






ROS">Auranofin
+++↓[D]ROS-dominant






ROS">Photodynamic Therapy (PDT)
+++0[L][O₂]ROS-dominant






ROS">Radiotherapy / Radiation
+++0[O₂]ROS-dominant






ROS">Doxorubicin
+++↓[D]ROS-dominant






ROS">Cisplatin
++↓[D][T]ROS-dominant






ROS">Salinomycin
++↓[D][T]ROS-dominant






ROS">Artemisinin / DHA
++↓[Fe][T]ROS-dominant






ROS">Sulfasalazine
++↓[C][T]ROS-dominant






ROS">FMD / fasting
++↓[M][C][O₂]ROS-dominant






ROS">Vitamin C (pharmacologic)
++↓[Fe][D]ROS-dominant






ROS">Silver nanoparticles
++±[F][D]ROS-dominant






ROS">Gambogic acid
++↓[D][T]ROS-dominant






ROS">Parthenolide
++↓[D][T]ROS-dominant






ROS">Plumbagin
++↓[D]ROS-dominant






ROS">Allicin
++↓[D]ROS-dominant






ROS">Ashwagandha (Withaferin A)
++↓[D][T]ROS-dominant






ROS">Berberine
++↓[D][M]ROS-dominant






ROS">PEITC
++↓[D][C]ROS-dominant






ROS">Methionine restriction
+↓[M][C][T]ROS-secondary






ROS">DCA
+±[M][T]ROS-secondary






ROS">Capsaicin
+±[D][T]ROS-secondary






ROS">Galloflavin
+0[D]ROS-secondary






ROS">Piperine
+±[D][F]ROS-secondary






ROS">Propyl gallate
+↓[D]ROS-secondary






ROS">Scoulerine
+?[D][T]ROS-secondary






ROS">Thymoquinone
±±[D][T]Dual redox






ROS">Emodin
±±[D][T]Dual redox






ROS">Alpha-lipoic acid (ALA)
±↑[D][M]NRF2-dominant






ROS">Curcumin
±↑/↓[D][F]NRF2-dominant






ROS">EGCG
±↑/↓[D][O₂]NRF2-dominant






ROS">Quercetin
±↑/↓[D][Fe]NRF2-dominant






ROS">Resveratrol
±↑[D][M]NRF2-dominant






ROS">Sulforaphane
±↑↑[D]NRF2-dominant






ROS">Lycopene
0↑—Antioxidant






ROS">Rosmarinic acid
0↑—Antioxidant






ROS">Citrate
00—Neutral


Scientific Papers found: Click to Expand⟱
7730- isoFl,    Anticancer Potential of Isoflavones: A Narrative Overview of Mechanistic Insights and Experimental Evidence from the Past Ten Years
- Review, Var, NA
Apoptosis↑, ROS↓, TumCCA↓, TumCMig↓, TumCI↓, MMP↓, angioG↓, ChemoSen↑, p‑Akt↓, p‑mTOR↓, cl‑PARP↑, cycA1/CCNA1↓, CycB/CCNB1↓, STAT3↓,
7732- isoFl,    Biological activities and therapeutic potential of soy isoflavones: a focus on anticancer activity
*Inflam↓, *ROS↓, Apoptosis↑, NOS2↑, *Aβ↓, *BioAv↓, *BioAv↑, *BioAv↝, *neuroP↑, *BBB↑, TNF-α↓, ROS↑, selectivity↑, ChemoSen↑, eff↝,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

ROS↓, 1,   ROS↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

MMP↓, 1,  

Cell Death(tgid=5) ⓘ

p‑Akt↓, 1,   Apoptosis↑, 2,  

DNA Damage & Repair(tgid=10) ⓘ

cl‑PARP↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

cycA1/CCNA1↓, 1,   CycB/CCNB1↓, 1,   TumCCA↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

p‑mTOR↓, 1,   STAT3↓, 1,  

Migration(tgid=13) ⓘ

TumCI↓, 1,   TumCMig↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

TNF-α↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ChemoSen↑, 2,   eff↝, 1,   selectivity↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

NOS2↑, 1,  
Total Targets: 19

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

ROS↓, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

Inflam↓, 1,  

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   BioAv↑, 1,   BioAv↝, 1,  

Functional Outcomes(tgid=23) ⓘ

neuroP↑, 1,  
Total Targets: 8

Scientific Paper Hit Count for: ROS, Reactive Oxygen Species
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:184  Target#:275  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page